KRd: the new KiD in the French myeloma induction class.

of in (TE) with

[1]  P. Moreau,et al.  Upfront Carfilzomib, Lenalidomide, Dexamethasone with Transplant in Multiple Myeloma Patients, the IFM KRd final results. , 2021, Blood.

[2]  G. Morgan,et al.  Carfilzomib, lenalidomide, dexamethasone, and cyclophosphamide (KRdc) as induction therapy for transplant-eligible, newly diagnosed multiple myeloma patients (Myeloma XI+): Interim analysis of an open-label randomised controlled trial. , 2021, PLoS medicine.

[3]  M. Boccadoro,et al.  Survival Analysis of Newly Diagnosed Transplant-Eligible Multiple Myeloma Patients in the Randomized Forte Trial , 2020 .

[4]  S. Lonial,et al.  Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial. , 2020, The Lancet. Oncology.

[5]  K. Griffith,et al.  Carfilzomib, lenalidomide, and dexamethasone plus transplant in newly diagnosed multiple myeloma. , 2020, Blood.

[6]  M. Arcila,et al.  Weekly Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab (wKRd-D) Combination Therapy Provides Unprecedented MRD Negativity Rates in Newly Diagnosed Multiple Myeloma: A Clinical and Correlative Phase 2 Study , 2019, Blood.

[7]  H. Goldschmidt,et al.  Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial. , 2017, The Lancet. Oncology.

[8]  N. Munshi,et al.  Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma , 2017, The New England journal of medicine.

[9]  S. Demo,et al.  Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma. , 2005, Blood.

[10]  N. Munshi,et al.  Association of Minimal Residual Disease With Superior Survival Outcomes in Patients With Multiple Myeloma: A Meta-analysis , 2017, JAMA oncology.